Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of intravenous JX-594 in sorafenib-naive advanced hepatocellular carcinoma
2012-000591-42Phase 2Terminated
- Sponsor
- Jennerex Therapeutics
- Start
- Jul 2012
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus in hepatocellular carcinoma (HCC), sponsored by Jennerex Therapeutics. Primary endpoint: Radiographic response rate. Started Jul 2012; status: terminated.
02
Drugs
vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2012-000591-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000591-42.